Volume 4.49 | Dec 17

Newsletter Issue
Hematopoiesis News 4.49 December 17, 2013
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Thymic Stromal Lymphopoietin-Mediated Extramedullary Hematopoiesis Promotes Allergic Inflammation
Scientists demonstrated a previously unrecognized role for thymic stromal lymphopoietin (TSLP) in promoting the population expansion of progenitor cells in the periphery and identify that TSLP-elicited progenitors differentiated into effector cells including macrophages, dendritic cells, and granulocytes and that these cells contributed to type 2 cytokine responses. [Immunity] Abstract | Graphical Abstract
[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Early Dynamic Fate Changes in Hemogenic Endothelium Characterized at the Single-Cell Level
Scientists showed that initiation of the hematopoietic program occurs in cells still embedded in the endothelial layer, and is accompanied by a previously unrecognized early loss of endothelial potential before hematopoietic stem cells emerge. [Nat Commun] Abstract

MOZ-Mediated Repression of p16INK4a Is Critical for the Self-Renewal of Neural and Hematopoietic Stem Cells
Scientists showed that the histone acetyltransferase MOZ controls the proliferation of both hematopoietic and neural stem cells by modulating the transcriptional repression of p16INK4a. [Stem Cells] Abstract

Low-Dose Triptolide in Combination with Idarubicin Induces Apoptosis in AML Leukemic Stem-Like KG1a Cell Line by Modulation of the Intrinsic and Extrinsic Factors
The ability of triptolide to induce apoptosis in leukemic stem cell (LSC)-like cells derived from acute myeloid leukemia (AML) cell line KG1a was investigated. LSC-like cells sorted from KG1a were subjected to cell cycle analysis and different treatments, and then followed by in vitro methyl thiazole tetrazolium bromide cytotoxicity assay. [Cell Death Dis] Full Article

The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34+ Hematopoietic Progenitor Cells
Scientists showed that by inhibiting the aryl hydrocarbon receptor with its antagonist StemRegenin 1, clinical-scale numbers of functional BDCA2+BDCA4+ plasmacytoid blood dendritic cells (DCs), BDCA1+ myeloid blood DCs (mDCs) and BDCA3+DNGR1+ mDCs can be efficiently generated from human CD34+ hematopoietic progenitor cells. [Stem Cells Dev] Abstract

An Unexpected Link between Notch Signaling and ROS in Restricting the Differentiation of Hematopoietic Progenitors in Drosophila
The authors address the role of Notch signaling in lamellocyte differentiation in response to wasp infection. They showed that Notch activity is moderately high and ubiquitous in all cells of the lymph gland lobes, with crystal cells exhibiting the highest levels. [Genetics] Abstract

Plerixafor Induces the Rapid and Transient Release of Stromal Cell-Derived Factor-1 Alpha from Human Mesenchymal Stromal Cells and Influences the Migration Behavior of Human Hematopoietic Progenitor Cells
Investigators quantified the impact of plerixafor on the interaction between human bone marrow derived mesenchymal stromal cells and human CD34+ hematopoietic progenitor cells. [Cell Tissue Res] Abstract


Cytokine and Chemokine Patterns Across One Hundred Days following Hematopoietic Stem Cell Transplantation in Children
Researchers mapped the cytokine response to hematopoietic stem cell transplantation (HSCT) by assaying fifty-one cytokines and chemokines each week for one hundred days in fifty-one children receiving allogeneic or autologous HSCT. [Biol Blood Marrow Transplant] Abstract

Antithymocyte Globulin in Reduced Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long Term Chronic GVHD
Researchers report a study conducted on 206 patients with a median age of 59 years, who received allogeneic hematopoietic stem cell transplantation prepared using fludarabine, 2 days of intravenous busulfan and 5 mg/kg of rabbit antithymocyte globulin, between 2005 and 2012. Grade III-IV acute and extensive chronic graft-versus-host diseases (GVHD) were 9% and 22%, respectively. [Biol Blood Marrow Transplant] Abstract

Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
MacroGenics Announces Presentation of Pre-Clinical Data on DART® Molecule Targeting CD123-Positive Leukemic Stem Cells
MacroGenics, Inc. announced the presentation of pre-clinical data for its proprietary DART® molecule, MGD006. These data demonstrate activity of MGD006, a bispecific molecule that redirects T cells against CD123-positive leukemic cells and results in the clearance of acute myeloid leukemia blasts in vitro and in vivo. [Press release from MacroGenics, Inc. discussing research presented at the 55th Annual Meeting of the American Society of Hematology, New Orleans] Press Release

Enter to Win: Free ISCT 2014 Conference Registration in Paris, France!
Athersys’ MultiStem® Stem Cell Therapy Receives Orphan Drug Designation in Europe for Prevention of Graft-versus-Host Disease
Athersys, Inc. announced that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion for the Company’s allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease. [Athersys, Inc.] Press Release

BioLineRx Announces Promising Initial Phase II Results of Acute Myeloid Leukemia Treatment
BioLineRx announced promising initial results for its BL-8040 drug candidate in a Phase II clinical trial for patients with relapsed or refractory acute myeloid leukemia. [BioLineRx] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Canadian Blood and Marrow Transplant Group 2014
June 11-14, 2014
Halifax, Nova Scotia

Visit our events page to see a complete list of events in the hematopoiesis research community.
NEW Postdoctoral Position – Hematopoietic Stem Cell Aging (Cincinnati Children’s Hospital Medical Center)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (Mount Sinai Medical Center)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Postdoctoral Fellow – Molecular Basis of Clonal Evolution in Leukemia (Northwestern University)

Postdoctoral Positions – Hematopoietic Stem Cell Physiology (University of Michigan)

Postdoctoral Position – Hematopoietic Stem Cell Research (Lund Stem Cell Center)

Director of Sponsored Programs (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us